News
CAI
31.98
-0.90%
-0.29
GRAIL sets new 52-week high as FDA panel backs cancer test
Seeking Alpha · 1d ago
Grail panel votes ‘closer than we expected,’ says BTIG
TipRanks · 1d ago
This test screens for 50 cancers — but whether Medicare and other health insurers will cover it hinges on FDA approval
MarketWatch · 2d ago
Caris Life Sciences: Adjusting My Position After A Recent Steep Incline (Downgrade)
Seeking Alpha · 3d ago
Goldman Sachs Remains a Buy on Caris Life Sciences, Inc. (CAI)
TipRanks · 4d ago
Weekly Report: what happened at CAI last week (0914-0918)?
Weekly Report · 4d ago
Caris Life Sciences: Diagnostics Growth With Room To Run
Seeking Alpha · 09/17 14:35
Strength Seen in Revvity (RVTY): Can Its 9.1% Jump Turn into More Strength?
NASDAQ · 09/16 09:14
Caris Life Sciences, Inc. (CAI) Soars 9.4%: Is Further Upside Left in the Stock?
NASDAQ · 09/16 07:51
10-Year Yield Tops 5%, Oil Storms Past $105: Stock Market Today
Benzinga · 09/15 17:27
Weekly Report: what happened at CAI last week (0907-0911)?
Weekly Report · 09/14 09:48
Caris Life Sciences Price Target Announced at $28.00/Share by UBS
Dow Jones · 09/09 13:26
Caris Life Sciences initiated with a Neutral at UBS
TipRanks · 09/09 11:21
Weekly Report: what happened at CAI last week (0831-0904)?
Weekly Report · 09/07 09:44
Caris Life Sciences to present new research at IASCL 2026
TipRanks · 09/02 12:45
Caris Life Sciences to Present New Research Advancing Precision Oncology at the IASLC 2026 World Conference on Lung Cancer
PR Newswire · 09/02 12:30
Weekly Report: what happened at CAI last week (0824-0828)?
Weekly Report · 08/31 09:48
These ten healthcare stocks posted the biggest gains over the past month
Seeking Alpha · 08/28 11:54
Caris Life Sciences Announces Publication Of Study Validating An AI-Driven Approach To First-Line Treatment Selection In Pancreatic Cancer In The Journal 'npj Precision Oncology'
Benzinga · 08/27 12:35
Nasdaq 100 Falls as Hot PCE Inflation Stirs Rate-Hike Bets: Stock Market Today
Benzinga · 08/26 16:58
More
Webull provides a variety of real-time CAI stock news. You can receive the latest news about Caris Life Sciences, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About CAI
Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.